Nordea Investment Management AB lifted its holdings in shares of Insulet Co. (NASDAQ:PODD – Get Rating) by 8.0% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 4,951 shares of the medical instruments supplier’s stock after buying an additional 366 shares during the period. Nordea Investment Management AB’s holdings in Insulet were worth $1,433,000 at the end of the most recent reporting period.
A number of other large investors have also modified their holdings of the business. Commerce Bank increased its stake in Insulet by 1.1% in the 3rd quarter. Commerce Bank now owns 3,253 shares of the medical instruments supplier’s stock valued at $746,000 after purchasing an additional 36 shares in the last quarter. Synovus Financial Corp increased its stake in Insulet by 1.0% in the 4th quarter. Synovus Financial Corp now owns 3,921 shares of the medical instruments supplier’s stock valued at $1,154,000 after purchasing an additional 37 shares in the last quarter. Moody National Bank Trust Division increased its stake in Insulet by 1.5% in the 4th quarter. Moody National Bank Trust Division now owns 2,829 shares of the medical instruments supplier’s stock valued at $833,000 after purchasing an additional 42 shares in the last quarter. Utah Retirement Systems increased its stake in Insulet by 0.4% in the 3rd quarter. Utah Retirement Systems now owns 12,365 shares of the medical instruments supplier’s stock valued at $2,836,000 after purchasing an additional 49 shares in the last quarter. Finally, Prudential Financial Inc. increased its stake in Insulet by 2.7% in the 3rd quarter. Prudential Financial Inc. now owns 2,024 shares of the medical instruments supplier’s stock valued at $468,000 after purchasing an additional 53 shares in the last quarter.
Insider Buying and Selling at Insulet
In other Insulet news, insider Charles Alpuche sold 4,000 shares of the firm’s stock in a transaction dated Thursday, March 9th. The stock was sold at an average price of $290.90, for a total value of $1,163,600.00. Following the transaction, the insider now directly owns 45,584 shares of the company’s stock, valued at $13,260,385.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In other news, CFO Wayde D. Mcmillan sold 1,255 shares of Insulet stock in a transaction dated Monday, April 3rd. The stock was sold at an average price of $318.31, for a total transaction of $399,479.05. Following the sale, the chief financial officer now directly owns 22,865 shares of the company’s stock, valued at $7,278,158.15. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider Charles Alpuche sold 4,000 shares of Insulet stock in a transaction dated Thursday, March 9th. The stock was sold at an average price of $290.90, for a total value of $1,163,600.00. Following the sale, the insider now directly owns 45,584 shares in the company, valued at $13,260,385.60. The disclosure for this sale can be found here. Insiders have sold 32,656 shares of company stock valued at $9,819,174 over the last three months. 0.90% of the stock is owned by company insiders.
Analysts Set New Price Targets
Insulet Price Performance
Shares of Insulet stock opened at $330.23 on Friday. The business’s fifty day moving average price is $314.37 and its 200 day moving average price is $299.50. The company has a current ratio of 3.47, a quick ratio of 2.46 and a debt-to-equity ratio of 2.72. Insulet Co. has a twelve month low of $187.07 and a twelve month high of $335.91. The stock has a market capitalization of $23.02 billion, a P/E ratio of 272.63 and a beta of 0.80.
Insulet (NASDAQ:PODD – Get Rating) last released its quarterly earnings data on Thursday, May 4th. The medical instruments supplier reported $0.23 EPS for the quarter, beating the consensus estimate of $0.09 by $0.14. Insulet had a return on equity of 17.29% and a net margin of 0.04%. The company had revenue of $358.10 million for the quarter, compared to analyst estimates of $330.21 million. During the same period last year, the company posted $0.40 earnings per share. The firm’s revenue was up 21.2% compared to the same quarter last year. As a group, research analysts anticipate that Insulet Co. will post 1.27 earnings per share for the current year.
Insulet Company Profile
Insulet Corp. is a medical device company, which engages in the development, manufacture, and marketing of an insulin infusion system for people with insulin-dependent diabetes. It specializes in diabetes supplies, including the OmniPod System, as well as other diabetes related products and supplies such as blood glucose testing supplies, traditional insulin pumps, pump supplies, and pharmaceuticals.
Recommended Stories
- Get a free copy of the StockNews.com research report on Insulet (PODD)
- An Updraft Is Brewing For DraftKings
- PepsiCo Hits “Sweet Spot” For APAC Growth, Macros Agree
- High-Risk Mullen Automotive Continues To Build Momentum
- 3 Recession-Proof Stocks With Nice Dividends
- Oracle Stock Climbs For Third Month, Still In Buy Range
Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.
